<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180421039368N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-06-20</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Hyoscine on Peristaltism and Cardiovascular Outcomes</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of Low Dose Hyoscine N-butyl Bromide Versus Usual Dose on Anti Motility Response and Cardiovascular Outcomes During Endoscopic Retrograde Cholangiopancreatography in patients with billiary tract disorder</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-06-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>350</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/30719</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible patients were randomized to two groups by Simple randomization method using computer-generated random numbers, Blinding description: in our study, we inform the patients about the necessity of hyoscine injection. The patients and physician (performing the procedure) are both blinded to the injected drug dosage (low or usual).
clinical care staff and analyzer are also blinded to the dosage of the drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Patients with underlying gallbladder and biliary tract disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: patients who receive low dose of hyoscine N-butylbromide ( 5 mg ) from Exir pharmaceutical company during cholangiopancreatography. The frequency of drug use depends on the duration of procedure and its interference with peristaltism. Intervention 2: Control group: patients who receive usual dose of hyoscin N-butylbromide ( 10mg ) from Exir pharmaceutical company during cholangiopancreatography. The frequency of drug use depends on the duration of procedure and its interference with peristaltism.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
all the data can be share after blinding the patients

When:
after publishing the results of study will be available

To whom:
all of the researchers can access to study's data

Conditions:
all the data will usable for analysis and comparison

Where to obtain:
requistion must be send by an email to the corespondent author
co respondent author : dr hassan salmanroghani
email: h.salmanroghani@ssu.ac.ir

How to obtain:
after sending request email to corespondent author, data of study will send to applier

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>hassan salmanroghani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>ebn sina blvd</address>
        <city>yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915814739</zip>
        <telephone>+98 35 3822 4000</telephone>
        <email>h.salmanroghani@ssu.ac.ir</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>hassan salmanroghani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>ebn sina blvd</address>
        <city>yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915814739</zip>
        <telephone>+98 35 3822 4000</telephone>
        <email>h.salmanroghani@ssu.ac.ir</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age above 18 years
Underlying disease needs cholangiopancreatography
Existence of Duodenal peristaltism that Interference with canolation</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Previous cardiovascular problems ( heart failure, myocardial infarction, second and third degree AV block )
Acute pancreatitis and cholangitis before procedure
Severe hypotension ( &lt;100 mmhg )
Pregnancy and breastfeeding
History of previous Allergy to Hyoscine</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K80-K87</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disorders of gallbladder, biliary tract and pancreas</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: patients who receive low dose of hyoscine N-butylbromide ( 5 mg ) from Exir pharmaceutical company during cholangiopancreatography. The frequency of drug use depends on the duration of procedure and its interference with peristaltism.</i_keyword>
      <i_keyword>Control group: patients who receive usual dose of hyoscin N-butylbromide ( 10mg ) from Exir pharmaceutical company during cholangiopancreatography. The frequency of drug use depends on the duration of procedure and its interference with peristaltism.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Comparison of anti motility duodenal response. Timepoint: Before starting the procedure, five minutes after the injection of hyoscine, and at the end of procedure. Method of measurement: observing the duodenal motility ( presence or absence of peristaltism) by physician during cholangiopancreatography (ERCP).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Comparison of blood pressure changes, cardiac rate and rhythm and o2 satuartion changes. Timepoint: Before starting the procedure, five minutes after the injection of hyoscine, and at the end of procedure. Method of measurement: cardiac monitoring for blood pressure and heart rate and pulsoximetry for o2 saturation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-03-12</approval_date>
        <contact_name>Ethics commitee of yazd University of Medical Sciences</contact_name>
        <contact_address>Ebn sina blvd, Shahid sadoughi hospital Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
